EF
APLS

Empowered Funds’s Apellis Pharmaceuticals APLS Stock Holding History

Empowered Funds’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.96M Buy
148,038
+134,657
+1,006% +$2.9M 0.04% 570
2025
Q4 		$336K Buy
13,381
+40
+0.3% +$938 0.01% 835
2025
Q3 		$302K Sell
13,341
-146
-1% -$3.4K ﹤0.01% 1591
2025
Q2 		$233K Buy
+13,487
New +$250K ﹤0.01% 1599

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Empowered Funds's APLS Position: Q1 2026 in Review

Empowered Funds increased its Apellis Pharmaceuticals (APLS) stake by 1,006% in Q1 2026, buying an estimated $2.9M and bringing the position to 148,038 shares worth $5.96M. The position accounts for 0.04% of the portfolio, ranked #570.

Empowered Funds first reported a position in APLS in Q2 2025 and has held it in 4 quarters since. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Empowered Funds held 148,038 shares of Apellis Pharmaceuticals worth $5.96M as of Q1 2026.
  • Empowered Funds bought 134,657 Apellis Pharmaceuticals shares in Q1 2026, an estimated $2.9M.
  • Apellis Pharmaceuticals made up 0.04% of Empowered Funds's portfolio in Q1 2026, its #570 holding.
  • Empowered Funds first reported a position in Apellis Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.